Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zirconium Zr-89-DFO-daratumumab
- Development stage
- Phase 2
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zirconium Zr-89-DFO-daratumumab is a radioimmunoconjugate consisting of daratumumab, a human IgG1 kappa monoclonal antibody targeting CD38, radiolabeled with zirconium-89 via desferrioxamine (DFO) conjugation. It is designed for CD38-targeted PET imaging of multiple myeloma, allowing non-invasive visualization of CD38-positive myeloma cells. This compound serves as a potential companion diagnostic for daratumumab therapy, helping to identify patients who may benefit from treatment. In clinical studies, it has demonstrated high specificity and sensitivity for detecting myeloma lesions, with successful visualization of both known and previously unknown sites of disease.
- Other names
- zirconium Zr 89-DFO-daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on zirconium Zr-89-DFO-daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zirconium Zr-89-DFO-daratumumab.